Recruiting
Phase 2

BMX-001

Sponsor:

NRG Oncology

Code:

NCT06532279

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Head and Neck Squamous Cell Carcinoma

Hypopharyngeal Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Best Practice

Biospecimen Collection

Cisplatin

Computed Tomography

Image Guided Radiation Therapy

Study Details

Brief summary:

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Head and Neck Squamous Cell Carcinoma

Hypopharyngeal Squamous Cell Carcinoma

Study ID

NCT06532279

Start date

Jun 23, 2025

Status verified date

Aug, 2026

Completion date

Jan 1, 2032

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must be planned to receive radiation and concurrent cisplatin chemotherapy as definitive therapy. Patients planned to receive concurrent cisplatin and radiation therapy in the adjuvant setting are not eligible.
  • At least two subsites (buccal mucosa, lips, retromolar trigone, floor of mouth, oral tongue, tonsil, soft palate, or hard palate) must have at least 1cc or 1% of the subsite volume receiving >= 50 Gy. In cases of uncertainty, the enrolling clinician can ensure coverage by inspecting the 50 Gy isodose line and using the table describing the anatomic boundaries of the individual subsites contained within the extended cavity contour. The two or more subsites receiving >= 50 Gy must be documented by the enrolling physician.
  • Pathologically confirmed (histologically or cytologically) squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharynx, or oral cavity.
  • P16 and/or human papillomavirus (HPV) status (via polymerase chain reaction \[PCR\] or in situ hybridization \[ISH\]) must be documented for patients with oropharynx cancer.
  • No patients with T0/Tx/unknown primary disease.
  • No definitive clinical or radiologic evidence of metastatic (M1) disease related to current diagnosis.
  • Able to receive intensity-modulated radiation therapy (IMRT) delivered as daily fractions of 2.0 Gy once per weekday with a cumulative radiation dose of 70 Gy.
  • Age >= 18.
  • Zubrod performance status of 0-2.
  • Potassium ≥ institutional lower limit of normal (LLN) and magnesium ≥ institutional LLN. Oral or intravenous (IV) replacement therapy of potassium or magnesium is permitted if parameters can be met after repletion.
  • Absolute neutrophil count (ANC) >= 1,500 cells/mm\^3.
  • Platelets >= 100,000 cells/mm\^3.
  • Hemoglobin >= 9.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] >= 10.0 g/dl is acceptable).
  • Adequate renal function defined as creatinine clearance (CrCL) > 50 mL/min by the Cockcroft-Gault formula.
  • Total bilirubin =< 2 x institutional upper limit of normal (ULN) (not applicable to patients with known Gilbert's syndrome).
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =< 3 x institutional ULN.
  • No prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer, e.g., breast cancer with irradiation of the supraclavicular fossa/level 4 neck.
  • No concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.
  • No prior history of gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed.
  • No current treatment of adjuvant post-operative (op) chemoradiation.
  • No systemic treatment with inducers or strong inhibitors of cytochrome P450 =< 4 days before registration. Note: Patients undergoing steroid treatment as a component of the anti-emetic regimen for cisplatin are eligible for the study. Treatment with the antifungal medications, nystatin, fluconazole , miconazole and clotrimazole are allowed.
  • No prior induction chemotherapy treatment.
  • No prior unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell skin carcinoma, resected T1-2N0M0 differentiated thyroid cancers, Ta bladder cancers, or low risk prostate cancer.
  • No clinically significant hearing impairment that precludes cisplatin, as per physician assessment.
  • No serious cardiovascular disease or cerebrovascular disease in the last 6 months prior to study enrollment; defined as a cerebrovascular accident, myocardial infarction, unstable angina, serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment, or current New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or admission within last 6 months for CHF exacerbation; (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification).
  • No valvular heart disease.
  • No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to enrollment.
  • No history or evidence upon physical/neurological examination of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication.
  • No acute bacterial, viral, or fungal infection requiring intravenous antimicrobials within 7 days of enrollment.
  • No history of chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration.
  • No known personal or family history of long QT Syndrome; no marked baseline prolongation of QT/corrected QT (QTc) interval (i.e., ≥ 2 electrocardiograms \[EKGs\] in prior 3 months of a QTc interval > 450 milliseconds (ms) for males and > 470 ms for females using the specific/usual choice by clinical center for correction factor.
  • Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities must be reversible to ≤ grade 1 with supplementation.
  • No poorly controlled hypertension (systolic blood pressure \[SBP\] > 160 and/or diastolic blood pressure \[DBP\] > 95) over 2 repeated measures within 30 days prior to registration.
  • No grade >= 2 oral mucositis per CTCAE version 5.0.
  • No grade >= 2 hypotension per CTCAE v. 5.0.
  • No medical necessity for anti-arrhythmics with significant risk of QTc prolongation such as class I and class III anti-arrhythmics. These include but are not limited to amiodarone, quinidine, dofetilide, sotalol, flecainide, and lidocaine.
  • No medical necessity for medications listed as prohibited.

  • For standard management of oral mucositis, clinicians may consult the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. The only intervention against mucositis that is supported by level I evidence is low-level laser therapy (LLLT). Honey is rated at level II and benzydamine, which isn't available in the United States (US), is rated at level III. There are no other positively rated interventions.
  • LLLT is prohibited in this study as its availability remains limited, it is not Food and Drug Administration (FDA) approved in the US, and it is considered investigational in many circumstances requiring enrollment in a dedicated protocol who requirements could conflict with this one. Therefore, institutions that use LLLT should only enroll patients who would not be eligible for (or do not want) that intervention. Honey is not on the list of prohibited medications for this study. Given the MASCC recommendation, benzydamine is allowed, although there is lack of availability in the United States of America (USA). The other listed prohibited medications are not recommended by MASCC and some are potentially harmful, such as glutamine, which is associated with mortality in patients receiving stem cell transplant.
  • No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
  • Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.

Study Design

Enrollment

98 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

placebo comparator: Arm 1 (placebo)

Patients receive cisplatin QW or Q3W and undergo image-guided intensity-modulated radiation therapy QD 5 days per week for 7 weeks per SOC. In addition to usual symptom management, patients receive placebo SC as early as 96 hours and no later than one hour prior to their first dose of radiation therapy, and as early as 96 hours and no later than 48 hours prior to first dose of cisplatin. Patients then receive placebo SC BIW for 8 weeks (16 doses). Patients also undergo CT and/or MRI on study and may optionally undergo collection of blood, serum, and/or plasma throughout the study.

experimental: Arm 2 (BMX-001)

Patients receive cisplatin QW or Q3W and undergo image-guided intensity-modulated radiation therapy QD 5 days per week for 7 weeks per SOC. In addition to usual symptom management, patients receive BMX-001 SC as early as 96 hours and no later than one hour prior to their first dose of radiation therapy, and as early as 96 hours and no later than 48 hours prior to first dose of cisplatin. Patients then receive BMX-001 SC BIW for 8 weeks (16 doses). Patients also undergo CT and/or MRI on study and may optionally undergo collection of blood, serum, and/or plasma throughout the study.

Interventions

Best Practice

Receive usual symptom management

Biospecimen Collection

Undergo collection of blood, serum, and/or plasma samples

Cisplatin

Given cisplatin

Computed Tomography

Undergo CT

Image Guided Radiation Therapy

Undergo image-guided radiation therapy

Intensity-Modulated Radiation Therapy

Undergo intensity-modulated radiation therapy

Magnetic Resonance Imaging

Undergo MRI

MnSOD Mimetic BMX-001

Given SC

Placebo Administration

Given SC

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Incidence of severe oral mucositis (SOM) [ Time Frame: From start of radiation through 4 weeks after completion of study treatment ]

Central Contacts and Locations

Locations

Arizona Center for Cancer Care - Gilbert

Recruiting

Gilbert, Arizona, United States, 85297

Contacts

Site Public Contact

480-278-8261penny.labriola@arizonaccc.com

Principal Investigator:

Steven E. Sckolnik

Arizona Center for Cancer Care-Peoria

Recruiting

Peoria, Arizona, United States, 85381

Contacts

Site Public Contact

623-773-2873

Principal Investigator:

Steven E. Sckolnik

Arizona Center for Cancer Care - Phoenix

Recruiting

Phoenix, Arizona, United States, 85027

Contacts

Site Public Contact

480-278-8261penny.labriola@arizonaccc.com

Principal Investigator:

Steven E. Sckolnik

Arizona Center for Cancer Care - Scottsdale

Recruiting

Scottsdale, Arizona, United States, 85258

Contacts

Site Public Contact

480-278-8261penny.labriola@arizonaccc.com

Principal Investigator:

Steven E. Sckolnik

Arizona Center for Cancer Care-Surprise

Recruiting

Surprise, Arizona, United States, 85374

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

Steven E. Sckolnik

Arizona Center for Cancer Care

Recruiting

Tempe, Arizona, United States, 85284

Contacts

Site Public Contact

480-278-8261penny.labriola@arizonaccc.com

Principal Investigator:

Steven E. Sckolnik

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Recruiting

Jonesboro, Arkansas, United States, 72401

Contacts

Site Public Contact

870-936-7066Emily.Carvell@bmhcc.org

Principal Investigator:

Shelby Lane

UC San Diego Health System - Encinitas

Recruiting

Encinitas, California, United States, 92024

Contacts

Site Public Contact

760-536-7700

Principal Investigator:

Karen M. Yun

UC San Diego Moores Cancer Center

Recruiting

La Jolla, California, United States, 92093

Contacts

Site Public Contact

858-822-5354cancercto@ucsd.edu

Principal Investigator:

Karen M. Yun

UC San Diego Medical Center - Hillcrest

Recruiting

San Diego, California, United States, 92103

Contacts

Site Public Contact

rhabbaba@health.ucsd.edu

Principal Investigator:

Karen M. Yun

Shaw Cancer Center

Recruiting

Edwards, Colorado, United States, 81632

Contacts

Site Public Contact

970-569-7429

Principal Investigator:

Patricia H. Hardenbergh

George Washington University Medical Center

Recruiting

Washington D.C., District of Columbia, United States, 20037

Contacts

Site Public Contact

202-741-2210

Principal Investigator:

Sharad Goyal

Sarasota Memorial Hospital-Venice

Recruiting

N. Venice, Florida, United States, 34275

Contacts

Site Public Contact

941-261-9000

Principal Investigator:

Kunal Saigal

Moffitt Cancer Center at SouthShore

Recruiting

Ruskin, Florida, United States, 33570

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Niema B. Razavian

Florida Cancer Specialists - Sarasota

Recruiting

Sarasota, Florida, United States, 34232

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

Kunal Saigal

Florida Cancer Specialists - Sarasota Downtown

Recruiting

Sarasota, Florida, United States, 34239

Contacts

Site Public Contact

239-274-9930ClinicalTrials@FLCancer.com

Principal Investigator:

Kunal Saigal

Sarasota Memorial Hospital

Recruiting

Sarasota, Florida, United States, 34239

Contacts

Site Public Contact

941-917-2225

Principal Investigator:

Kunal Saigal

Sarasota Memorial Health Care Center at University Parkway

Recruiting

Sarasota, Florida, United States, 34243

Contacts

Site Public Contact

941-917-6519

Principal Investigator:

Kunal Saigal

Moffitt Cancer Center-International Plaza

Recruiting

Tampa, Florida, United States, 33607

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Niema B. Razavian

Moffitt Cancer Center - McKinley Campus

Recruiting

Tampa, Florida, United States, 33612

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Niema B. Razavian

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33612

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Niema B. Razavian

Florida Cancer Specialists - Venice Pinebrook

Recruiting

Venice, Florida, United States, 34275

Contacts

Site Public Contact

239-274-9930ClinicalTrials@FLCancer.com

Principal Investigator:

Kunal Saigal

Moffitt Cancer Center at Wesley Chapel

Recruiting

Wesley Chapel, Florida, United States, 33544

Contacts

Site Public Contact

800-679-0775ClinicalTrials@moffitt.org

Principal Investigator:

Niema B. Razavian

OSF Saint Joseph Medical Center

Recruiting

Bloomington, Illinois, United States, 61701

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Bloomington

Recruiting

Bloomington, Illinois, United States, 61704

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Canton

Recruiting

Canton, Illinois, United States, 61520

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Site Public Contact

312-695-1301cancer@northwestern.edu

Principal Investigator:

Laila A. Gharzai

Carle at The Riverfront

Recruiting

Danville, Illinois, United States, 61832

Contacts

Site Public Contact

800-446-5532Research@Carle.com

Principal Investigator:

Sinisa Stanic

Northwestern Medicine Cancer Center Kishwaukee

Recruiting

DeKalb, Illinois, United States, 60115

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Laila A. Gharzai

Carle Physician Group-Effingham

Recruiting

Effingham, Illinois, United States, 62401

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Sinisa Stanic

Illinois CancerCare-Eureka

Recruiting

Eureka, Illinois, United States, 61530

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Galesburg

Recruiting

Galesburg, Illinois, United States, 61401

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Northwestern Medicine Cancer Center Delnor

Recruiting

Geneva, Illinois, United States, 60134

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Laila A. Gharzai

Illinois CancerCare-Kewanee Clinic

Recruiting

Kewanee, Illinois, United States, 61443

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Macomb

Recruiting

Macomb, Illinois, United States, 61455

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Carle Physician Group-Mattoon/Charleston

Recruiting

Mattoon, Illinois, United States, 61938

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Sinisa Stanic

Northwestern Medicine Oak Brook

Recruiting

Oak Brook, Illinois, United States, 60523

Contacts

Site Public Contact

nctnprogram_rhlccc@northwestern.edu

Principal Investigator:

Laila A. Gharzai

Northwestern Medicine Orland Park

Recruiting

Orland Park, Illinois, United States, 60462

Contacts

Site Public Contact

nctnprogram_rhlccc@northwestern.edu

Principal Investigator:

Laila A. Gharzai

Illinois CancerCare-Ottawa Clinic

Recruiting

Ottawa, Illinois, United States, 61350

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Pekin

Recruiting

Pekin, Illinois, United States, 61554

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Peoria

Recruiting

Peoria, Illinois, United States, 61615

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

OSF Saint Francis Medical Center

Recruiting

Peoria, Illinois, United States, 61637

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Peru

Recruiting

Peru, Illinois, United States, 61354

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Illinois CancerCare-Princeton

Recruiting

Princeton, Illinois, United States, 61356

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Carle Cancer Center

Recruiting

Urbana, Illinois, United States, 61801

Contacts

Site Public Contact

800-446-5532Research@carle.com

Principal Investigator:

Sinisa Stanic

Northwestern Medicine Cancer Center Warrenville

Recruiting

Warrenville, Illinois, United States, 60555

Contacts

Site Public Contact

630-352-5360Donald.Smith3@nm.org

Principal Investigator:

Laila A. Gharzai

Illinois CancerCare - Washington

Recruiting

Washington, Illinois, United States, 61571

Contacts

Site Public Contact

309-243-3605andersonj@illinoiscancercare.com

Principal Investigator:

Bryan A. Faller

Baptist Health Floyd

Recruiting

New Albany, Indiana, United States, 47150

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

William A. Porter

McFarland Clinic - Ames

Recruiting

Ames, Iowa, United States, 50010

Contacts

Site Public Contact

515-239-4734ksoder@mcfarlandclinic.com

Principal Investigator:

Joseph J. Merchant

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Recruiting

Ankeny, Iowa, United States, 50023

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Mercy Hospital

Recruiting

Cedar Rapids, Iowa, United States, 52403

Contacts

Site Public Contact

319-365-4673

Principal Investigator:

Deborah W. Wilbur

Oncology Associates at Mercy Medical Center

Recruiting

Cedar Rapids, Iowa, United States, 52403

Contacts

Site Public Contact

319-363-2690

Principal Investigator:

Deborah W. Wilbur

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Recruiting

Clive, Iowa, United States, 50325

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Iowa Methodist Medical Center

Recruiting

Des Moines, Iowa, United States, 50309

Contacts

Site Public Contact

515-241-6727

Principal Investigator:

Seema Harichand-Herdt

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Recruiting

Des Moines, Iowa, United States, 50309

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

Mercy Medical Center - Des Moines

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Richard L. Deming

UI Health Care Mission Cancer and Blood - Laurel Clinic

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

University of Iowa/Holden Comprehensive Cancer Center

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

Site Public Contact

800-237-1225

Principal Investigator:

Carryn M. Anderson

UI Health Care Mission Cancer and Blood - Waukee Clinic

Recruiting

Waukee, Iowa, United States, 50263

Contacts

Site Public Contact

515-241-3305

Principal Investigator:

Seema Harichand-Herdt

University of Kansas Cancer Center

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Site Public Contact

913-588-3671KUCC_Navigation@kumc.edu

Principal Investigator:

Christopher Lominska

Salina Regional Health Center

Recruiting

Salina, Kansas, United States, 67401

Contacts

Site Public Contact

785-452-7038mleepers@srhc.com

Principal Investigator:

Christopher Lominska

University of Kansas Hospital-Westwood Cancer Center

Recruiting

Westwood, Kansas, United States, 66205

Contacts

Site Public Contact

913-588-3671KUCC_Navigation@kumc.edu

Principal Investigator:

Christopher Lominska

Baptist Health Hardin

Recruiting

Elizabethtown, Kentucky, United States, 42701

Contacts

Site Public Contact

270-706-5470

Principal Investigator:

William A. Porter

Greater Baltimore Medical Center

Recruiting

Baltimore, Maryland, United States, 21204

Contacts

Site Public Contact

443-849-3706

Principal Investigator:

Kruti Patel

Boston Medical Center

Recruiting

Boston, Massachusetts, United States, 02118

Contacts

Site Public Contact

617-638-8265

Principal Investigator:

Minh T. Truong

McLaren Cancer Institute-Bay City

Recruiting

Bay City, Michigan, United States, 48706

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Clarkston

Recruiting

Clarkston, Michigan, United States, 48346

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

Wayne State University/Karmanos Cancer Institute

Recruiting

Detroit, Michigan, United States, 48201

Contacts

Site Public Contact

800-527-6266ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

Weisberg Cancer Treatment Center

Recruiting

Farmington Hills, Michigan, United States, 48334

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Flint

Recruiting

Flint, Michigan, United States, 48532

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

Karmanos Cancer Institute at McLaren Greater Lansing

Recruiting

Lansing, Michigan, United States, 48910

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Lapeer Region

Recruiting

Lapeer, Michigan, United States, 48446

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Macomb

Recruiting

Mount Clemens, Michigan, United States, 48043

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Central Michigan

Recruiting

Mount Pleasant, Michigan, United States, 48858

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren Cancer Institute-Northern Michigan

Recruiting

Petoskey, Michigan, United States, 49770

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

McLaren-Port Huron

Recruiting

Port Huron, Michigan, United States, 48060

Contacts

Site Public Contact

313-576-9790ctoadmin@karmanos.org

Principal Investigator:

Brian K. Yeh

Miller-Dwan Hospital

Recruiting

Duluth, Minnesota, United States, 55805

Contacts

Site Public Contact

218-786-3308CancerTrials@EssentiaHealth.org

Principal Investigator:

Bret E. Friday

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Recruiting

Columbus, Mississippi, United States, 39705

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Baptist Cancer Center-Grenada

Recruiting

Grenada, Mississippi, United States, 38901

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Baptist Memorial Hospital and Cancer Center-Union County

Recruiting

New Albany, Mississippi, United States, 38652

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Baptist Memorial Hospital and Cancer Center-Oxford

Recruiting

Oxford, Mississippi, United States, 38655

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Baptist Memorial Hospital and Cancer Center-Desoto

Recruiting

Southhaven, Mississippi, United States, 38671

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Saint Francis Medical Center

Recruiting

Cape Girardeau, Missouri, United States, 63703

Contacts

Site Public Contact

573-334-2230sfmc@sfmc.net

Principal Investigator:

Bryan A. Faller

Lake Regional Hospital

Recruiting

Osage Beach, Missouri, United States, 65065

Contacts

Site Public Contact

573-302-2768clinicaltrials@lakeregional.com

Principal Investigator:

Jay W. Carlson

Renown Regional Medical Center

Recruiting

Reno, Nevada, United States, 89502

Contacts

Site Public Contact

702-384-0013research@sncrf.org

Principal Investigator:

Abhinand V. Peddada

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Site Public Contact

800-639-6918cancer.research.nurse@dartmouth.edu

Principal Investigator:

Philip E. Schaner

University of New Mexico Cancer Center

Recruiting

Albuquerque, New Mexico, United States, 87106

Contacts

Site Public Contact

505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu

Principal Investigator:

Moises Harari-Turquie

Montefiore Medical Center-Einstein Campus

Recruiting

The Bronx, New York, United States, 10461

Contacts

Site Public Contact

718-379-6866eskwak@montefiore.org

Principal Investigator:

Rafi Kabarriti

Montefiore Medical Center - Moses Campus

Recruiting

The Bronx, New York, United States, 10467

Contacts

Site Public Contact

718-379-6866eskwak@montefiore.org

Principal Investigator:

Rafi Kabarriti

Atrium Health Stanly/LCI-Albemarle

Recruiting

Albemarle, North Carolina, United States, 28002

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Carolinas Medical Center/Levine Cancer Institute

Recruiting

Charlotte, North Carolina, United States, 28203

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Atrium Health Pineville/LCI-Pineville

Recruiting

Charlotte, North Carolina, United States, 28210

Contacts

Site Public Contact

980-442-2000

Principal Investigator:

Matthew C. Ward

Atrium Health University City/LCI-University

Recruiting

Charlotte, North Carolina, United States, 28262

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Atrium Health Cabarrus/LCI-Concord

Recruiting

Concord, North Carolina, United States, 28025

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Site Public Contact

888-275-3853

Principal Investigator:

Jared R. Robbins

CaroMont Regional Medical Center

Recruiting

Gastonia, North Carolina, United States, 28054

Contacts

Site Public Contact

704-834-2810tammy.cozad@caromonthealth.org

Principal Investigator:

Jeffrey G. Kuremsky

Levine Cancer Institute-Gaston

Recruiting

Gastonia, North Carolina, United States, 28054

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Hayworth Cancer Center

Recruiting

High Point, North Carolina, United States, 27262

Contacts

Site Public Contact

336-802-2500

Principal Investigator:

Ryan T. Hughes

Atrium Health Union/LCI-Union

Recruiting

Monroe, North Carolina, United States, 28112

Contacts

Site Public Contact

980-442-2000

Principal Investigator:

Matthew C. Ward

Atrium Health Cleveland/LCI-Cleveland

Recruiting

Shelby, North Carolina, United States, 28150

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Wake Forest University Health Sciences

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

Site Public Contact

336-713-6771

Principal Investigator:

Ryan T. Hughes

Summa Health System - Akron Campus

Recruiting

Akron, Ohio, United States, 44304

Contacts

Site Public Contact

330-375-4221cancerresearch@summahealth.org

Principal Investigator:

Desiree E. Doncals

Aultman Health Foundation

Recruiting

Canton, Ohio, United States, 44710

Contacts

Site Public Contact

330-363-7274ClinicalReserachDept@aultman.com

Principal Investigator:

Jessica L. Wobb

University of Cincinnati Cancer Center-UC Medical Center

Recruiting

Cincinnati, Ohio, United States, 45219

Contacts

Site Public Contact

513-584-7698cancer@uchealth.com

Principal Investigator:

Sara Medek

Ohio State University Comprehensive Cancer Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Site Public Contact

800-293-5066Jamesline@osumc.edu

Principal Investigator:

Sung Jun Ma

University of Cincinnati Cancer Center-West Chester

Recruiting

West Chester, Ohio, United States, 45069

Contacts

Site Public Contact

513-584-7698cancer@uchealth.com

Principal Investigator:

Sara Medek

University of Oklahoma Health Sciences Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Site Public Contact

405-271-8777ou-clinical-trials@ouhsc.edu

Principal Investigator:

Christina Henson

Chambersburg Hospital

Recruiting

Chambersburg, Pennsylvania, United States, 17201

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

Amit B. Shah

Ephrata Cancer Center

Recruiting

Ephrata, Pennsylvania, United States, 17522

Contacts

Site Public Contact

717-721-4840

Principal Investigator:

Amit B. Shah

UPMC Hillman Cancer Center Erie

Recruiting

Erie, Pennsylvania, United States, 16505

Contacts

Site Public Contact

412-864-7716ClinicalResearchServices@upmc.edu

Principal Investigator:

Yvonne M. Mowery

UPMC Cancer Center at UPMC Horizon

Recruiting

Farrell, Pennsylvania, United States, 16121

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

Yvonne M. Mowery

Adams Cancer Center

Recruiting

Gettysburg, Pennsylvania, United States, 17325

Contacts

Site Public Contact

877-441-7957

Principal Investigator:

Amit B. Shah

UPMC Cancer Centers - Arnold Palmer Pavilion

Recruiting

Greensburg, Pennsylvania, United States, 15601

Contacts

Site Public Contact

724-838-1900

Principal Investigator:

Yvonne M. Mowery

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Recruiting

Harrisburg, Pennsylvania, United States, 17109

Contacts

Site Public Contact

717-724-6765klitchfield@PINNACLEHEALTH.org

Principal Investigator:

Yvonne M. Mowery

Penn State Milton S Hershey Medical Center

Recruiting

Hershey, Pennsylvania, United States, 17033-0850

Contacts

Site Public Contact

717-531-3779CTO@hmc.psu.edu

Principal Investigator:

Min Yao

Sechler Family Cancer Center

Recruiting

Lebanon, Pennsylvania, United States, 17042

Contacts

Site Public Contact

717-741-8303doxenberg@wellspan.org

Principal Investigator:

Amit B. Shah

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Recruiting

Mechanicsburg, Pennsylvania, United States, 17050

Contacts

Site Public Contact

412-389-5208haneydl@upmc.edu

Principal Investigator:

Yvonne M. Mowery

UPMC Cancer Center - Monroeville

Recruiting

Monroeville, Pennsylvania, United States, 15146

Contacts

Site Public Contact

412-339-5294Roster@nrgoncology.org

Principal Investigator:

Yvonne M. Mowery

UPMC Hillman Cancer Center - Monroeville

Recruiting

Monroeville, Pennsylvania, United States, 15146

Contacts

Site Public Contact

412-864-7716ClinicalResearchServices@upmc.edu

Principal Investigator:

Yvonne M. Mowery

UPMC Hillman Cancer Center - New Castle

Recruiting

New Castle, Pennsylvania, United States, 16105

Contacts

Site Public Contact

412-389-5208haneydl@upmc.edu

Principal Investigator:

Yvonne M. Mowery

UPMC-Saint Margaret

Recruiting

Pittsburgh, Pennsylvania, United States, 15215

Contacts

Site Public Contact

412-784-4900

Principal Investigator:

Yvonne M. Mowery

University of Pittsburgh Cancer Institute (UPCI)

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Site Public Contact

412-647-8073

Principal Investigator:

Yvonne M. Mowery

UPMC-Shadyside Hospital

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Site Public Contact

412-621-2334

Principal Investigator:

Yvonne M. Mowery

UPMC-Passavant Hospital

Recruiting

Pittsburgh, Pennsylvania, United States, 15237

Contacts

Site Public Contact

412-367-6454

Principal Investigator:

Yvonne M. Mowery

UPMC-Saint Clair Hospital Cancer Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15243

Contacts

Site Public Contact

412-502-3920

Principal Investigator:

Yvonne M. Mowery

WellSpan Health-York Cancer Center

Recruiting

York, Pennsylvania, United States, 17403

Contacts

Site Public Contact

877-441-7957

Principal Investigator:

Amit B. Shah

Lancaster Radiation Therapy Center

Recruiting

Lancaster, South Carolina, United States, 29720

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Rock Hill Radiation Therapy Center

Recruiting

Rock Hill, South Carolina, United States, 29730

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Levine Cancer Institute-Rock Hill

Recruiting

Rock Hill, South Carolina, United States, 29732

Contacts

Site Public Contact

800-804-9376

Principal Investigator:

Matthew C. Ward

Baptist Memorial Hospital and Cancer Center-Collierville

Recruiting

Collierville, Tennessee, United States, 38017

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

University of Tennessee - Knoxville

Recruiting

Knoxville, Tennessee, United States, 37920

Contacts

Site Public Contact

865-544-9773

Principal Investigator:

Christopher Brett

Baptist Memorial Hospital and Cancer Center-Memphis

Recruiting

Memphis, Tennessee, United States, 38120

Contacts

Site Public Contact

901-226-1366BCCclintrials@bmhcc.org

Principal Investigator:

Shelby Lane

Dartmouth Cancer Center - North

Recruiting

Saint Johnsbury, Vermont, United States, 05819

Contacts

Site Public Contact

800-639-6918cancer.research.nurse@hitchcock.org

Principal Investigator:

Philip E. Schaner

VCU Massey Cancer Center at Stony Point

Recruiting

Richmond, Virginia, United States, 23235

Contacts

Site Public Contact

ctoclinops@vcu.edu

Principal Investigator:

Erin R. Alesi

VCU Massey Comprehensive Cancer Center

Recruiting

Richmond, Virginia, United States, 23298

Contacts

Site Public Contact

804-628-6430CTOclinops@vcu.edu

Principal Investigator:

Erin R. Alesi

Langlade Hospital and Cancer Center

Recruiting

Antigo, Wisconsin, United States, 54409

Contacts

Site Public Contact

715-623-9869Juli.Alford@aspirus.org

Principal Investigator:

Andrew J. Huang

Northwest Wisconsin Cancer Center

Recruiting

Ashland, Wisconsin, United States, 54806

Contacts

Site Public Contact

218-786-3308CancerTrials@EssentiaHealth.org

Principal Investigator:

Bret E. Friday

Froedtert Menomonee Falls Hospital

Recruiting

Menomonee Falls, Wisconsin, United States, 53051

Contacts

Site Public Contact

262-257-5100

Principal Investigator:

Musaddiq J. Awan

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Site Public Contact

414-805-3666

Principal Investigator:

Musaddiq J. Awan

Zablocki Veterans Administration Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53295

Contacts

Site Public Contact

888-469-6614

Principal Investigator:

Evan Liang

Drexel Town Square Health Center

Recruiting

Oak Creek, Wisconsin, United States, 53154

Contacts

Site Public Contact

414-805-0505

Principal Investigator:

Musaddiq J. Awan

Aspirus Cancer Care - James Beck Cancer Center

Recruiting

Rhinelander, Wisconsin, United States, 54501

Contacts

Site Public Contact

715-847-2353Beth.Knetter@aspirus.org

Principal Investigator:

Andrew J. Huang

Aspirus Cancer Care - Stevens Point

Recruiting

Stevens Point, Wisconsin, United States, 54481

Contacts

Site Public Contact

715-847-2353Beth.Knetter@aspirus.org

Principal Investigator:

Andrew J. Huang

Aspirus Regional Cancer Center

Recruiting

Wausau, Wisconsin, United States, 54401

Contacts

Site Public Contact

877-405-6866

Principal Investigator:

Andrew J. Huang

Froedtert West Bend Hospital/Kraemer Cancer Center

Recruiting

West Bend, Wisconsin, United States, 53095

Contacts

Site Public Contact

414-805-0505

Principal Investigator:

Musaddiq J. Awan

Aspirus Cancer Care - Wisconsin Rapids

Recruiting

Wisconsin Rapids, Wisconsin, United States, 54494

Contacts

Site Public Contact

715-422-7718

Principal Investigator:

Andrew J. Huang

More Information

Sponsor

NRG Oncology

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by NRG Oncology on 2026-08-17.